Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 576

Sort by

Sort Order Select

Journal Articles

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Gloria F. Gerber, Xuan Yuan, Jia Yu, Benjamin A. Y. Cher, Evan M. Braunstein, Shruti Chaturvedi, Robert A. Brodsky

Blood (2021) 137 (26): 3670–3673.

https://doi.org/10.1182/blood.2021011548

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky

Blood (2021) 137 (10): 1304–1309.

https://doi.org/10.1182/blood.2019003812

Published: 2021

Journal Articles

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

Lova Sun, Daria V. Babushok

Blood (2020) 136 (1): 36–49.

https://doi.org/10.1182/blood.2019000940

Published: 2020

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors

Mai Aly, MD BSc, MS, Hassan Awada, MD, Douaa Sayed, MD, Esam ElBeih, MD, Raafat Abdel El Fattah, MD, Refat Fathy Abdel-Aal Naseer, MD, Reem Alagooz, MD, Rania Hafez, MD, Almetwaly M. Sultan, MD, Nahla El-Sharkawy, MD, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 5652.

https://doi.org/10.1182/blood-2019-132183

Published: 2019

Journal Articles

Outcomes of Haploidentical Haematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Haemoglobinuria

Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD, Xiaowen Tang, Huiying Qiu, PhD, Yue Han, MD, Zhengming Jin, MD, Suning Chen, Aining Sun, PhD, Qingyuan Wang, MD

Blood (2019) 134 (Supplement_1): 5730.

https://doi.org/10.1182/blood-2019-131808

Published: 2019

Journal Articles

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Matheus Vescovi, MD PhD, Iara Baldim Rabelo Gomes, MD PhD, Ismael Dale Cotrim Guerreiro da Silva, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2229.

https://doi.org/10.1182/blood-2019-126241

Published: 2019

Journal Articles

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Hassan Awada, MD, Shafia Rahman, MBBS, Cassandra M Kerr, MS, Jibran Durrani, Vera Adema, PhD, Ashwin Kishtagari, MBBS, Sunisa Kongkiatkamon, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 2499.

https://doi.org/10.1182/blood-2019-131918

Published: 2019

Journal Articles

Deep Immunoprofiling By Flow Cytometry and NGS Reveals Distinct T Cell Profile in Pediatric Hepatitis-Associated Aplastic Anemia

Michaela Novakova, Michael Svaton, MD, Martina Sukova, MD, Veronika Kanderova, MSc, PhD, Nikos Darzentas, PhD, Lenka Kramna, MSc, PhD, Ondrej Cinek, Prof., MD PhD, Dagmar Pospisilova, Prof MD PhD, Jan Trka, Prof., MD PhD, Ondrej Hrusak, MD PhD, Jan Stary, Prof., MD PhD, Ester Mejstrikova, MD PhD, Eva Fronkova, MD PhD

Blood (2019) 134 (Supplement_1): 2508.

https://doi.org/10.1182/blood-2019-127986

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Magali Le Garff-Tavernier, Agathe Pruvot Debliquis, PharmD, Thomas Boyer, MD, Jean-Philippe Vial, MD, Véronique Harrivel, MD, Anne-Catherine Lhoumeau, PhD PharmD, Marie-Christine Jacob, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD, Bernard Drenou, MD PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 1218.

https://doi.org/10.1182/blood-2019-123415

Published: 2019

Journal Articles

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Fathima Mohiyaddin Ayyalil, MBBS, FRACP,FRCPA, Samantha J Montague, BSc, PhD, Sarah Hicks, Amandeep Kaur, PhD, Anila Jahangiri, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Philip Crispin, MBBS, FRACP, FRCPA, Yujie Zheng, Xu Tienan, Lucy Coupland, PhDBSc,RN, Woei Ming Lee, James D'Rozario, MBBS, FRACP, FRCPA, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 4884.

https://doi.org/10.1182/blood-2019-130291

Published: 2019

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

https://doi.org/10.1182/blood-2019-124571

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

How I treat paroxysmal nocturnal hemoglobinuria

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

A complementary new drug for PNH

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors

Outcomes of Haploidentical Haematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Haemoglobinuria

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Deep Immunoprofiling By Flow Cytometry and NGS Reveals Distinct T Cell Profile in Pediatric Hepatitis-Associated Aplastic Anemia

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only